Giant Cell Arteritis Epidemiology Forecast Insight

DelveInsight’s ‘Giant Cell Arteritis (GCA) - Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted GCA epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Giant Cell Arteritis Understanding

Giant Cell Arteritis (GCA) is a medical condition that can cause pain and swelling in blood vessels. Blood vessels are tubes that carry blood around the body. GCA affects arteries, which are the largest of the three types of blood vessels. Arteries take blood with oxygen in from the heart to different parts of the body. GCA commonly causes headaches, joint pain, facial pain, fever, and difficulties with vision, and sometimes permanent visual loss in one or both eyes. Because the disease is relatively uncommon and because the disease can cause so many different symptoms, the diagnosis of GCA can be difficult to make. With appropriate therapy, GCA is an eminently treatable, controllable, and often curable disease.

 

This disease used to be called “temporal arteritis” because the temporal arteries, which course along the sides of the head just in front of the ears (to the temples) can become inflamed. It is a chronic form of vasculitis of the large and medium vessels, especially involving the extracranial branches of the carotid arteries, in particular, the temporal artery, with the involvement of the axillary, femoral and iliac arteries too. Arterial wall inflammation leads to luminal occlusion and tissue ischemia, which is responsible for the clinical manifestations of the disease. A substantial number of patients affected by GCA present head and neck symptoms, including ocular, neurological and otorhino laryngological manifestations.

 

According to the National Institute of Health (NIH), the world’s older population continues to grow at an unprecedented rate, and today around 8.5% of the population are aged 65 and over, and according to a new report, this percentage is projected to jump to nearly 17% of the world’s population by 2050. Cardiovascular disease (CVD), specifically Coronary heart disease (CHD), stroke, congestive heart failure (CHF), and peripheral artery disease became the leading cause of chronic disease morbidity and mortality in industrialized countries. Inflammatory conditions such as rheumatoid arthritis, systemic lupus erythematous, psoriatic arthritis, and giant cell arteritis are associated with an increased risk of CHD.

 

Giant Cell Arteritis (GCA) Diagnosis

While a clinical presentation of headache, jaw claudication, scalp tenderness, fever and other systemic symptoms and serum markers are together highly suggestive of the disease, diagnosis can be challenging in those cases in which classic symptoms are lacking. No one test can confirm the presence of GCA. To help the doctor reach a diagnosis, the doctor will observe the symptoms and note down the medical history of the patients. The doctors can also conduct a physical examination, partly focusing on the arteries in the temples and if the patient has GCA, the arteries may feel hard or tender.

 

Then the patients are required to go through some testing procedures. Typically, if a doctor suspects the GCA, the first tests ordered are blood tests looking for inflammation. These may include Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) blood tests; high levels of either signify inflammation suggesting GCA. Imaging tests may also help pinpoint GCA as well. A specialized ultrasound can be performed in some medical centers to evaluate for inflammation of temporal arteries and the large arteries in the upper chest. Other types of imaging studies may also be performed if the doctor suspects inflammation in the aorta (in the chest) or its branches in the chest and upper extremities.

Epidemiology Perspective by DelveInsight

The Giant Cell Arteritis epidemiology division provides insights about historical and current Giant Cell Arteritis patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

In the year 2020, the total prevalent cases of Giant Cell Arteritis was 435,887 cases in the 7MM which are expected to grow during the study period, i.e., 2018–2030.

 

The disease epidemiology covered in the report provides historical as well as forecasted Giant Cell Arteritis epidemiology [segmented as Total Prevalent Cases of Giant Cell Arteritis, Total Subtype-specific Cases of Giant Cell Arteritis, Total Age group-specific Cases of Giant Cell Arteritis,  Total Clinical Manifestation-specific Cases of Giant Cell Arteritis, and Total Treated Cases of Giant Cell Arteritis] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country Wise- GCA Epidemiology

  • Estimates show that the highest cases of GCA in the 7MM were in United States, followed by the United Kingdom, France, Italy, Germany, Spain, and Japan in 2020.
  • In the United States, the total number of prevalent cases of Giant Cell Arteritis was 244,438 cases in the year 2020 which are expected to grow during the study period, i.e., 2018–2030.
  • In the year 2020, the total prevalent cases of Giant Cell Arteritis were 190,573 cases in EU-5 which are expected to grow during the study period, i.e., 2018–2030.
  • In Japan, the total number of prevalent cases of Giant Cell Arteritis was 875 cases in the year 2020 which are expected to grow during the study period, i.e., 2018–2030.

Scope of the Report

  • The Giant Cell Arteritis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
  • The Giant Cell Arteritis Report and Model provide an overview of the risk factors and global trends of GCA in the seven major markets (7MM: The United States, Germany, France, Italy, Spain, the United Kingdom, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Giant Cell Arteritis in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of Giant Cell Arteritis.
  • The report provides the segmentation of the Giant Cell Arteritis epidemiology by total prevalent cases in the 7MM.
  • The report provides the segmentation of the Giant Cell Arteritis epidemiology by total Subtype-specific cases in the 7MM.
  • The report provides the segmentation of the Giant Cell Arteritis epidemiology by total age group-specific cases in the 7MM.
  • The report provides the segmentation of the Giant Cell Arteritis epidemiology by total clinical manifestation-specific cases in the 7MM.
  • The report provides the segmentation of the Giant Cell Arteritis epidemiology by total treated cases in the 7MM.

Report Highlights

  • 10-Year Forecast of Giant Cell Arteritis epidemiology
  • 7MM Coverage 
  • Total Prevalent Cases of Giant Cell Arteritis 
  • Total Subtype-specific Cases of Giant Cell Arteritis
  • Total Age group-specific Cases of Giant Cell Arteritis 
  • Total Clinical Manifestation-specific Cases of Giant Cell Arteritis 
  • Total Treated Cases of Giant Cell Arteritis

KOL-Views 

We interview KOL’s and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM concerning the patient population of Giant Cell Arteritis?
  • What are the key findings of the Giant Cell Arteritis epidemiology across the 7MM and which country will have the highest number of patients during the study period (2018–2030)?
  • What would be the total number of patients of Giant Cell Arteritis across the 7MM during the study period (2018–2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the study period (2018–2030)?
  • At what CAGR the patient population is expected to grow in the 7MM during the study period (2018–2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of Giant Cell Arteritis?

Reasons to buy

The Giant Cell Arteritis Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Giant Cell Arteritis market
  • Quantify patient populations in the global Giant Cell Arteritis market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the gender that presents the best opportunities for Giant Cell Arteritis therapeutics in each of the markets covered
  • Understand the magnitude of Giant Cell Arteritis population by its age group-specificity
  • The Giant Cell Arteritis epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
  • The Giant Cell Arteritis Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 10-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation 
  • Disease Risk and Burden
  • Risk of disease by the segmentation 
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. Executive Summary of Giant Cell Arteritis (GCA)

3.1. Key Events

4. Epidemiology Methodology

5. Disease Background and Overview

5.1. Introduction

5.2. Causes of GCA

5.3. Signs and symptoms of GCA

5.4. Complications of GCA

5.5. Clinical Manifestations of GCA

5.6. Pathophysiology of GCA

5.7. Pathogenesis of GCA

6. Diagnosis of Giant Cell Arteritis (GCA)

6.1. Diagnostic Algorithm

6.1.1. Journal of Medical Case Reports diagnostic algorithm

6.2. Diagnostic Criteria

6.3. Diagnosis Tests

6.4. Physical Examination

6.5. Blood Tests

6.6. Imaging Tests

6.7. Temporal artery biopsy (TAB)

6.8. Differential Diagnosis

7. Diagnostic guidelines

7.1. American College of Rheumatology (ACR) diagnostic guidelines for GCA

7.2. European League against Rheumatism (EULAR) guidelines for the diagnosis of GCA

7.3. The British Society for Rheumatology (BSR) and British Health Professionals in Rheumatology (BHPR) diagnostic guidelines for GCA

7.4. The French Study Group for Larger vessel vasculitis (GEFA) recommendations for diagnosis of GCA

8. Epidemiology and Patient Population

8.1. Key Findings

8.2. Epidemiology of Giant Cell Arteritis

8.3. Epidemiology Scenario

8.3.1. Total Prevalent Cases of Giant Cell Arteritis

8.3.2. Total Subtype-specific Cases of Giant Cell Arteritis

8.3.3. Total Age group-specific Cases of Giant Cell Arteritis

8.3.4. Total Clinical Manifestation-specific Cases of Giant Cell Arteritis

8.3.5. Total Treated Cases of Giant Cell Arteritis

9. KOL Views

10. Appendix

10.1. Bibliography

10.2. Report Methodology

11. DelveInsight Capabilities

12. Disclaimer

13. About DelveInsight

List of Table

Table 1: Summary of Giant Cell Arteritis (GCA), Market, Epidemiology, and Key Events (2018-2030)

Table 2: Revised ACR criteria (rACR) for diagnosis of GCA

Table 3: Recommendations for diagnostic testing in GCA

Table 4: Recommendations concerning GCA diagnosis

Table 5: Total Prevalent Cases of Giant Cell Arteritis (2018-2030)

Table 6: Total Subtype-specific Cases of Giant Cell Arteritis (2018-2030)

Table 7: Total Age group-specific Cases of Giant Cell Arteritis (2018-2030)

Table 8: Total Clinical Manifestation-specific Cases of Giant Cell Arteritis (2018-2030)

Table 9: Total Treated Cases of Giant Cell Arteritis (2018-2030)

List of Figures

Figure 1: Epidemiology and Market Methodology

Figure 2: Profile of head showing the GCA in the human body

Figure 3: Brief description of Giant Cell Arteritis

Figure 4: Causes of GCA

Figure 5: Symptoms of GCA

Figure 6: Complication of GCA

Figure 7: Clinical Manifestations involved in GCA

Figure 8: Pathophysiology of GCA

Figure 9: Diagnostic algorithm for evaluation of suspected GCA

Figure 10: Diagnostic tests involved in GCA

Figure 11: Preoperative appearance of a patient with a prominent left superficial temporal artery

Figure 12: "Halo-sign" on temporal and axillary arteries

Figure 13: Cranial involvement pattern

Figure 14: Sagittal PET (A, B), coronal PET and fused PET/CT (C-F), and axial PET (G-I)

Figure 15: Showing the temporal artery for biopsy

Figure 16: Figure showing picture of biopsy in a patient

Figure 17: Total Prevalent Cases of Giant Cell Arteritis in the 7MM (2018-2030)

Figure 18: Total Subtype-specific Cases of Giant Cell Arteritis in the 7MM (2018-2030)

Figure 19: Total Age group-specific Cases of Giant Cell Arteritis in the 7MM (2018-2030)

Figure 20: Total Clinical Manifestation-specific Cases of Giant Cell Arteritis in the 7MM (2018-2030)

Figure 21: Total Treated Cases of Giant Cell Arteritis in the 7MM (2018-2030)

Forward to Friend

Need A Quote